Marinomed Biotechnologie GmbH
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Marinomed Biotechnologie GmbH
I-Mab sets commercial plans with Sinopharm for felzartamab in multiple myeloma. Legochem and Antengene team up on antibody-drug conjugates, Luoxin licenses respiratory drug from Marinomed.
The company announced positive results for reproxalap from its Phase III INVIGORATE trial in allergic conjunctivitis, which may be a good sign for its dry eye disease studies.
EU and UK regulators are vying for vaccine filings, and the EMA will consider changing the terms of the marketing authorization for remdesivir after a WHO panel advised against its use in COVID-19. An Austrian biotech firm is investigating the prophylactic potential of a carrageenan-based spray.
If Landos goes public late next year, its financing strategy will align with venture capital and IPO trends observed in a new Jefferies report. Also, D&D Pharmatech raises $137.1m in VC cash, Sonnet secures up to $100m and the CF Foundation commits up to $15m to Arcturus.
- Medical Devices
- OTC, Consumer
- Drug Discovery Tools
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Other Names / Subsidiaries
- Marinomed Biotech AG
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.